Board Meeting Details

The Board Meeting of Sai Parenterals Limited was held on Sunday, November 1, 2026 at 12:30 p.m. at the Registered Office of the Company in Hyderabad. The meeting concluded at 2:30 p.m.

Key Decisions Approved

1. Financial Results Approval

The Board considered and approved:

  • Un-audited financial results (Standalone and Consolidated) for the quarter and half year ended September 30, 2026
  • Limited Review Reports (Standalone and Consolidated) for the quarter and half year ended September 30, 2026

2. Acquisition of SP Analytics Private Limited

The Board approved the acquisition of the remaining 25% equity shareholding in M/s. SP Analytics Private Limited, a subsidiary in which the company already holds 75%, thereby making it a wholly owned subsidiary.

Acquisition Details:

  • Target Entity: M/s. SP Analytics Private Limited
  • Industry: Pharma Sector
  • Acquisition falls within Related Party Transactions under Companies Act, 2013 and SEBI LODR Regulations, 2015
  • Promoters/Promoter Group have interest in the entity being acquired
  • Transaction to be undertaken at arm's length basis
  • Consideration: Cash
  • Cost of acquisition: ₹25,000 for 2,500 equity shares of face value ₹10/- each
  • Percentage acquired: Remaining 25% equity shareholding
  • Indicative completion period: On or before December 31, 2026
  • Entity background: Incorporated on November 16, 2023, main object is testing, analysis and examination of pharmaceuticals, medicines, drugs and related materials
  • Reported nil turnover during last three financial years

3. Constitution of Management Committee

The Board approved the constitution of a Management Committee for smooth functioning and administration convenience of the Company.

Committee Members:

1. Anil Kumar Karusala - Managing Director (Chairman)

2. Vijitha Gorrepati - Whole Time Director (Member)

3. Kunal Kakumanu - Executive Director (Member)

4. Arvind Gannimitta - Chief Operating Officer (Member)

5. Ashwani Singh Bisht - Company Secretary & Compliance Officer (Member)

4. Completion of Saicriti Pharma Acquisition

Pursuant to the Board approval on August 11, 2026, the Company has completed the acquisition of 60% of the equity share capital of Saicriti Pharma Private Limited. Consequently, Saicriti Pharma Private Limited has become a subsidiary of the Company with effect from the date of completion of the acquisition.

Financial Results Summary

Consolidated Financial Results (₹ in Millions)

Quarter Ended September 30, 2026:

  • Revenue from Operations: ₹37,359
  • Other Income: ₹3,741
  • Total Income: ₹41,100
  • Profit Before Tax: ₹19,679
  • Profit After Tax: ₹10,510
  • Basic EPS: ₹2.38

Half Year Ended September 30, 2026:

  • Revenue from Operations: ₹73,590
  • Other Income: ₹7,460
  • Total Income: ₹81,050
  • Profit Before Tax: ₹19,679
  • Profit After Tax: ₹10,510
  • Basic EPS: ₹2.38

Comparative Figures (Quarter Ended September 30, 2025):

  • Revenue from Operations: ₹19,401.8
  • Profit After Tax: ₹7,764
  • Basic EPS: ₹1.79

Standalone Financial Results (₹ in Millions)

Quarter Ended September 30, 2026:

  • Revenue from Operations: ₹52,779
  • Other Income: ₹3,414
  • Total Income: ₹56,192
  • Profit Before Tax: ₹11,830
  • Profit After Tax: ₹8,875
  • Basic EPS: ₹2.01

Half Year Ended September 30, 2026:

  • Revenue from Operations: ₹105,687
  • Other Income: ₹7,006
  • Total Income: ₹112,693
  • Profit Before Tax: ₹20,527
  • Profit After Tax: ₹15,361
  • Basic EPS: ₹3.48

Financial Position

Consolidated Balance Sheet (as at September 30, 2026, ₹ in Millions)

  • Total Assets: ₹13,198.08
  • Total Equity: ₹5,081.03
  • Non-Current Liabilities: ₹3,476.08
  • Current Liabilities: ₹4,640.97
  • Property, Plant & Equipment: ₹825.82
  • Right of Use Assets: ₹1,255.35
  • Capital Work-in-Progress: ₹2,692.70
  • Inventories: ₹1,822.04
  • Cash & Cash Equivalents: ₹1,293.30

Standalone Balance Sheet (as at September 30, 2026, ₹ in Millions)

  • Total Assets: ₹6,357.81
  • Total Equity: ₹5,005.06
  • Non-Current Liabilities: ₹397.59
  • Current Liabilities: ₹955.17
  • Property, Plant & Equipment: ₹467.64
  • Inventories: ₹644.78
  • Trade Receivables: ₹1,462.00
  • Cash & Cash Equivalents: ₹1,236.84

Auditor Review

The unaudited financial results were reviewed by the Audit Committee and approved by the Board on November 1, 2026. Statutory Auditors R Kabra & Co. LLP carried out a Limited Review and issued unmodified conclusions for both standalone and consolidated financial results.